Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: firstname.lastname@example.org
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Aid delivered to four besieged towns in Syria: ICRC
25 Sep 2016 at 7:25pm
Seventy trucks of humanitarian aid were delivered on Sunday to four besieged towns in Syria for the first time in almost six months, the International Committee of the Red Cross (ICRC) said. The aid organisation said convoys were delivered to Madaya and Zabdani near Damascus and to the villages of al Foua and Kefraya in Idlib province in the north west. Kefraya and al-Foua, in Idlib province in northwest Syria, have around 20,000 people, according to U.N. estimates, and have been surrounded by insurgents since April 2015.
Mother uncovers lasting impact of baby son's organ donation
25 Sep 2016 at 4:14pm
An ultrasound showed one of Sarah Gray's unborn twins was missing part of his brain, a fatal birth defect. His brother was born healthy but Thomas lived just six days. Latching onto hope for something ...
Doctors 'prescribe' fresh produce with help from food banks
25 Sep 2016 at 10:13am
OAK FOREST, Ill. (AP) ? The idea is simple: Load fresh fruits and vegetables into a refrigerator truck and drive it to a health clinic, then have a doctor write a "prescription" for food to improve the diets of low-income people with diabetes and high blood pressure.
AIDS pageant in Uganda seeks to stem stigma, discrimination
25 Sep 2016 at 6:53am
KAMPALA, Uganda (AP) ? When she was younger, Tryphena Natukunda's mother discouraged her from swallowing her antiretroviral medicines among strangers or even distant relatives.
UK doctors call off strike action
24 Sep 2016 at 2:13pm
The British Medical Association (BMA) had planned a full withdrawal of labor by junior doctors on Oct. 5-7 and 10-11, Nov. 14-18 and Dec. 5-9, which would have been the longest stoppages in the nearly 70-year history of the National Health Service. Junior doctors - a term covering recent medical school graduates right through to doctors who have been working for well over a decade - have staged a series of walkouts over a new work contract the government plans to impose next month. The BMA said its decision to suspend the action follows feedback from doctors, patients and the public, and discussions with NHS England about the ability of the NHS to maintain a safe service if industrial action were to go ahead.
Thousands march in Dublin, abroad for Irish abortion rights
24 Sep 2016 at 9:18am
By Padraic Halpin DUBLIN (Reuters) - Thousands of protestors marched in Dublin, and Irish expatriates joined in demonstrations around the world on Saturday, to put pressure on the Irish government to hold a referendum to repeal restrictive abortion laws. Regulations in the once stridently Catholic Ireland are among the strictest in the world and next month Prime Minister Enda Kenny will call a citizens' assembly to advise the government on whether a vote should be held to boost access to abortion. Demonstrators marched in the rain on government buildings from Dublin's main thoroughfare of O'Connell Street, bringing traffic to a standstill by the River Liffey as they chanted, beat drums and held placards saying "My Body, My Choice".
Feds push back on states targeting Planned Parenthood funds
24 Sep 2016 at 7:37am
WICHITA, Kan. (AP) ? The Obama administration has proposed barring states and other recipients of federal family planning grants from placing their own eligibility restrictions on where the money can go, which would undermine the efforts of 13 Republican-led states to prevent such money from going to Planned Parenthood.
The 10 Healthiest Places to Live in America
24 Sep 2016 at 2:38am
From Hawaii to New Hampshire, here's where to move for your health.
Medically unfit' Fury out of Klitschko rematch
24 Sep 2016 at 2:34am
Next month's world heavyweight title rematch between champion Tyson Fury and Ukrainian Vladimir Klitschko was called off on Friday for a second time with the Briton ruled "medically unfit". The fight was due to be held on Oct. 29 in Manchester, having been originally postponed in July when Fury suffered an ankle injury. "Tyson has this week been declared medically unfit to fight," his promoters Hennessy Sports said in a statement without elaborating.
"We don't need to grow more food to cut hunger in Africa" - activist
24 Sep 2016 at 1:23am
By Alex Whiting TURIN, Italy (Thomson Reuters Foundation) - As a young university student of agriculture, Edie Mukiibi believed the latest hybrid seeds which promised bumper crops were the answer to improving the lot of maize farmers in his part of Uganda. He persuaded many to buy the seeds, while working part-time promoting them in Kiboga district in central Uganda. But the consequences were "terrible", he said. When I went back to talk with the farmers I could feel their pain," Mukiibi said. Even worse, the new crops could not be grown with any other crops, so the farmers were left with nothing to fall back on except the bills they had run up for the pesticides, herbicides and fertilisers the maize required, he said. "This is when I started working with farmers ... to diversify (their) farming," said Mukiibi, now vice president of Slow Food International, a grassroots movement of farmers, chefs, activists and academics campaigning to improve the quality of food and the lives of producers.
U.S. presidential contest takes center stage for investors
23 Sep 2016 at 8:00pm
Who becomes the next U.S. president will be a primary focus for Wall Street next week and beyond, starting on Monday with the first debate between candidates Hillary Clinton and Donald Trump. While the White House race has so far had little discernible effect on the market, that may soon change as polls show a tightening race. Clinton's once-comfortable lead in opinion polls has evaporated, and with just over six weeks until Election Day, some investors see a toss-up contest creating volatility in certain sectors, including health insurers, drugmakers and industrials.
Cowboys, heat and rain: 'Magnificent Seven' talk challenging shoot
23 Sep 2016 at 3:02pm
By Piya Sinha-Roy LOS ANGELES (Reuters) - Bringing the American Wild West to life was no easy task, just ask the cast of "The Magnificent Seven," who endured scorching heat and torrential rain in wool costumes in the Louisiana summer. "We had a lot of lightning, thunder issues where we had to shut (production) down, but the heat was just constant," Denzel Washington, who plays bounty hunter Sam Chisholm, told Reuters. "The Magnificent Seven," a remake of the 1960 classic, is directed by Antoine Fuqua and opens in theaters on Friday.
Fury pulls out of Klitschko rematch through injury
23 Sep 2016 at 3:01pm
BERLIN (Reuters) - The world heavyweight title rematch between champion Tyson Fury and Ukrainian Vladimir Klitschko on Oct. 29 has been called off for a second time with the Briton ruled "medically unfit". "Tyson has this week been declared medically unfit to fight," Fury's promoters Hennessy Sports said in a brief statement on Friday. "Medical specialists have advised that the condition is too severe to allow him to participate in the rematch and that he will require treatment before going back into the ring." (Reporting by Karolos Grohmann; Editing by Tony Jimenez)
Boxing-'Medically unfit' Fury out of Klitschko rematch
23 Sep 2016 at 3:01pm
* Heavyweight fight called off for second time * Champion Fury's condition is "too severe" (Adds quotes, details) BERLIN, Sept 23 (Reuters) - Next month's world heavyweight title rematch between champion Tyson Fury and Ukrainian Vladimir Klitschko was called off on Friday for a second time with the Briton ruled "medically unfit". The fight was due to be held on Oct. 29 in Manchester, having been originally postponed in July when Fury suffered an ankle injury. "Tyson has this week been declared medically unfit to fight," his promoters Hennessy Sports said in a statement without elaborating.
FDA approves Amgen's copy of AbbVie arthritis drug Humira
23 Sep 2016 at 2:51pm
The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar version of AbbVie's top-selling arthritis drug, Humira. The drug, Amjevita, known also as adalimumab-atto, was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis and other conditions. Amjevita is the fourth biosimilar to be approved by the FDA and is expected to be sold at a discount to the original drug.